Seim H et al
Overall, oral semaglutide was efficacious and safe in individuals with renal dysfunction, demonstrating its potential as an antidiabetic medication that may improve kidney function in patients with T2D with decreased renal function [51]
This partnership supports your bodys natural detoxification and antioxidant defenses, allowing it to break down and remove toxins and oxidative byproducts more efficiently
About the GEMINI-1 Clinical Trial The GEMINI-1 clinical trial was a multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical study (NCT06396429) conducted by Hengrui in China to evaluate the efficacy and safety of HRS9531 injection in adults (18 years of age) with obesity (BMI 28 kg/m 2 ) or overweight (BMI 24 kg/m 2 ) and at least one weight-related comorbidity without diabetes
This makes obesity one of the leading risk factors for multimorbidity 2 , negatively impacting metabolic, cardiovascular (CV), mental and physical health, as well as mortality 3,4
Lancet 388 , 505517 (2016)